Rimegepant sulfate Chemical Properties

InChI

InChI=1/C28H28F2N6O3.H2O4S/c29-20-6-1-4-17(23(20)30)18-8-9-22(25-19(24(18)31)5-2-12-32-25)39-28(38)35-14-10-16(11-15-35)36-21-7-3-13-33-26(21)34-27(36)37;1-5(2,3)4/h1-7,12-13,16,18,22,24H,8-11,14-15,31H2,(H,33,34,37);(H2,1,2,3,4)/t18-,22+,24-;/s3

InChIKey

SBWRYPRKGHWPOH-FDZFFRPLNA-N

SMILES

S(O)(O)(=O)=O.O=C1NC2=NC=CC=C2N1C1CCN(C(=O)O[C@@H]2CC[C@@H](C3C=CC=C(F)C=3F)[C@H](N)C3=CC=CN=C23)CC1 |&1:22,25,34,r|

Rimegepant sulfate Usage And Synthesis

Description

Rimegepant sulfate is a small molecule, highly selective calcitonin gene-related peptide antagonist (CGRP) developed by Biohaven Pharmaceutical Holdings, Inc. and approved by the FDA for the acute treatment of migraine. rimegepant and ubrogepant are the only CGRP antagonists with oral bioavailability. Because of the absence of vasoconstrictive properties observed with oral CGRP antagonists, the use of rimegepant is safer and more reliable in patients with contraindications to standard therapy^[1].

Uses

Rimegepant sulfate is indicated for the acute treatment of migraine and for the preventive treatment of episodic migraine in adults.

Trade name

Nurtec

Mechanism of action

Remegipam sulfate is used for the acute treatment of migraine by antagonizing CGRP receptors, reducing CGRP-induced vasodilation and pain signal transmission.

Side effects

Common side effects of Rimegepant sulfate are nausea, which may be severe enough to cause shortness of breath, difficulty breathing; swelling of the face, eyes, mouth, throat, tongue, or lips; rash, measles; and itching.

Synthesis

Rimegepant sulfate is prepared by the reaction of rimegepant and water.
Step: With sulfuric acid In ethanol at 20 - 70℃; Solvent; Temperature.

References

[1] J S. Rimegepant: First Approval.[J]. Drugs, 2020, 80 7: 741-746. DOI:10.1007/s40265-020-01301-3.